| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MO40598 | CTRIAL-IE 18-47 | Lymphoma. |
This study will evaluate the safety and efficacy of Polatuzumab Vedotin (Pola) in combination with Mabthera plus Gemcitabine plus Oxaliplatin (R-GemOx) versus R-GemOx |
DSSG Group: Lymphoma & blood cancers
Millennium Pevonedistat P2001
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Millennium Pevonedistat P2001 | CTRIAL-IE 16-08 | Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia |
This study will asses the efficacy and safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine |
FEDR-MF-002/FREEDOM-2
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| FEDR-MF-002/FREEDOM-2 | CTRIAL-IE 19-40 | Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis |
This study will assess the efficacy and safety of fedratinib compared to best available therapy. |
CALLS (INCB 84344-401)
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CALLS (INCB 84344-401) | 18-48 | Participants with Chronic Myeloid Leukaemia (CML) and Philadelphia-positive Acute Lymphoid Leukaemia (Ph+ALL) who are being treated with their first or subsequent tyrosine kinase inhibitor (TKI) therapy. |
The purpose of this observational study is to evaluate the prevalence of mutations in patients with Chronic Myeloid Leukaemia (CML) who meet the European Leukaemia Net (ELN) criteria for warning or failure and patients with Philadelphia-positive Acute Lymphoid Leukaemia (Ph+ALL) with detectable BCR-ABL currently being treated with first or subsequent Tyrosine Kinase Inhibitor (TKI) therapy in the UK, Ireland, or France using Next-Generation Sequencing. |
Paradigme (LYMRIT-37-01)
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Paradigme (LYMRIT-37-01) | 18-15 | Follicular Lymphoma that did not respond to treatment or recurred after chemotherapy or immunotherapy treatment. |
To investigate the efficacy and safety of a new drug called Betalutin®. One dose of Betalutin® is given to patients. Betalutin® is an antibody which targets a protein on lymphoma cancer cells together with radioactivity to kill the cancer cells. Two doses of Betalutin® are used in this clinical trial and all patients receive Betalutin®. Patients will be requested to return to clinic for up to 5 years to have their cancer assessed and to collect any side effects. |
CheckMate 744
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CheckMate 744 | 17-07 | Children, adolescents, and young adults with Classic Hodgkin Lymphoma whose disease has come back or did not respond to initial treatment. |
The purpose of this study is to determine whether certain drug combinations are safe and effective. |